Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1999-11

AUTHORS

J.F.R. Robertson, A. Howell, A. Buzdar, M. von Euler, D. Lee

ABSTRACT

BACKGROUND: This paper reports on the clinical relevance of durable static disease (SD) (> or = 24 weeks) in breast cancer patients treated with the aromatase inhibitor anastrozole. PATIENTS AND METHODS: All patients were part of two prospective, randomised, multicentre studies in postmenopausal women with advanced disease in which megestrol acetate was compared with anastrozole 1 mg. Survival from initiation of treatment was analysed by the response type, i.e., complete response (CR)/partial response (PR), static disease (SD) (> or = 24 weeks), or progressive disease (PD), achieved on therapy. RESULTS: Median survival with anastrozole 1 mg was similar between patients who obtained CR/PR and SD (> or = 24 weeks). Similarly, no difference in survival was observed in patients treated with megestrol acetate who achieved CR/PR and SD. With both treatments patients with CR/PR and SD had improved survival over those patients with PD within 24 weeks. There was no difference between treatment arms for patients showing PD within 24 weeks. CONCLUSIONS: These data confirm that durable SD (> or = 24 weeks) is a clinically useful remission criterion in postmenopausal women with advanced breast cancer with predictive value for overall survival. It also confirms the value of this endpoint with anastrozole, a new generation aromatase inhibitor. More... »

PAGES

157-162

Identifiers

URI

http://scigraph.springernature.com/pub.10.1023/a:1006391902868

DOI

http://dx.doi.org/10.1023/a:1006391902868

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1037141890

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/10674881


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents, Hormonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aromatase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Enzyme Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Europe", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Megestrol Acetate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nitriles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Postmenopause", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Triazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United States", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Nottingham City Hospital", 
          "id": "https://www.grid.ac/institutes/grid.412920.c", 
          "name": [
            "Department of Surgery, City Hospital, Nottingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Robertson", 
        "givenName": "J.F.R.", 
        "id": "sg:person.07764637207.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07764637207.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Christie Hospital", 
          "id": "https://www.grid.ac/institutes/grid.415720.5", 
          "name": [
            "Christie Hospital, Manchester, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Howell", 
        "givenName": "A.", 
        "id": "sg:person.01005610111.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01005610111.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "D Anderson Cancer Center, Houston, Texas, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Buzdar", 
        "givenName": "A.", 
        "id": "sg:person.015030714417.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015030714417.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "D Anderson Cancer Center, Houston, Texas, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "von Euler", 
        "givenName": "M.", 
        "id": "sg:person.01264747205.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264747205.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lee", 
        "givenName": "D.", 
        "id": "sg:person.0644622466.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644622466.12"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1002/(sici)1097-0142(19980915)83:6<1142::aid-cncr13>3.0.co;2-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005407624"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0277-5379(89)90259-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007284388"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0014-2964(77)90234-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014483121"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(97)00178-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030310702"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0277-5379(88)90046-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045342488"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1023/a:1008226721932", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056302667"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.1.52", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074511209"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1996.14.7.2000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082907367"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1998.16.2.453", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083213024"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1999-11", 
    "datePublishedReg": "1999-11-01", 
    "description": "BACKGROUND: This paper reports on the clinical relevance of durable static disease (SD) (> or = 24 weeks) in breast cancer patients treated with the aromatase inhibitor anastrozole.\nPATIENTS AND METHODS: All patients were part of two prospective, randomised, multicentre studies in postmenopausal women with advanced disease in which megestrol acetate was compared with anastrozole 1 mg. Survival from initiation of treatment was analysed by the response type, i.e., complete response (CR)/partial response (PR), static disease (SD) (> or = 24 weeks), or progressive disease (PD), achieved on therapy.\nRESULTS: Median survival with anastrozole 1 mg was similar between patients who obtained CR/PR and SD (> or = 24 weeks). Similarly, no difference in survival was observed in patients treated with megestrol acetate who achieved CR/PR and SD. With both treatments patients with CR/PR and SD had improved survival over those patients with PD within 24 weeks. There was no difference between treatment arms for patients showing PD within 24 weeks.\nCONCLUSIONS: These data confirm that durable SD (> or = 24 weeks) is a clinically useful remission criterion in postmenopausal women with advanced breast cancer with predictive value for overall survival. It also confirms the value of this endpoint with anastrozole, a new generation aromatase inhibitor.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1023/a:1006391902868", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1092777", 
        "issn": [
          "0167-6806", 
          "1573-7217"
        ], 
        "name": "Breast Cancer Research and Treatment", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "58"
      }
    ], 
    "name": "Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer", 
    "pagination": "157-162", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "b0ee88b7d380edf686d98efe9ae85fd2efaa46de1ec710caa12aab0c2ba6ae42"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "10674881"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8111104"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1023/a:1006391902868"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1037141890"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1023/a:1006391902868", 
      "https://app.dimensions.ai/details/publication/pub.1037141890"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T14:06", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8660_00000500.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1023/A:1006391902868"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1023/a:1006391902868'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1023/a:1006391902868'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1023/a:1006391902868'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1023/a:1006391902868'


 

This table displays all metadata directly associated to this object as RDF triples.

197 TRIPLES      21 PREDICATES      54 URIs      37 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1023/a:1006391902868 schema:about N05ee7b0cae384a99b33a0824f1809843
2 N1759b8cc43cb4770a66f6dae74d7039c
3 N2cc5db6280b348918b0adeba7db2bb33
4 N597b39e163894b06ad13599370862beb
5 N63be74ff62844af4bc250f25a77890cf
6 N64b0c3b4cb164f9d8a58473267c5bf49
7 N6b763fa9f6f34c9ba59501de656129a6
8 N7ab0c64d0c054f3cabf23663bdc3632e
9 N842546ac067d4373ba12022e50e0bf45
10 Nb039f62a09c648e3aef307c1ae2234c6
11 Nb9f0f6ca1a0148f5b1fb2fa3b0c84be4
12 Nbcec6cca4fd94ee2bc6372d68169972a
13 Nc11e2f2028a543da80ebba3c3884b1ec
14 Ncbf50214f8e0489db42af7b0e70e2f9f
15 Nd0e6d00e56a04dde8ab70cc824c5e054
16 Nd14243beb21543a4a79ca31a0bc4767a
17 anzsrc-for:11
18 anzsrc-for:1112
19 schema:author Na42453c62b12468986ac837091dfe892
20 schema:citation https://doi.org/10.1002/(sici)1097-0142(19980915)83:6<1142::aid-cncr13>3.0.co;2-5
21 https://doi.org/10.1016/0014-2964(77)90234-1
22 https://doi.org/10.1016/0277-5379(88)90046-6
23 https://doi.org/10.1016/0277-5379(89)90259-9
24 https://doi.org/10.1016/s0959-8049(97)00178-0
25 https://doi.org/10.1023/a:1008226721932
26 https://doi.org/10.1200/jco.1996.14.7.2000
27 https://doi.org/10.1200/jco.1998.16.2.453
28 https://doi.org/10.1200/jco.1999.17.1.52
29 schema:datePublished 1999-11
30 schema:datePublishedReg 1999-11-01
31 schema:description BACKGROUND: This paper reports on the clinical relevance of durable static disease (SD) (> or = 24 weeks) in breast cancer patients treated with the aromatase inhibitor anastrozole. PATIENTS AND METHODS: All patients were part of two prospective, randomised, multicentre studies in postmenopausal women with advanced disease in which megestrol acetate was compared with anastrozole 1 mg. Survival from initiation of treatment was analysed by the response type, i.e., complete response (CR)/partial response (PR), static disease (SD) (> or = 24 weeks), or progressive disease (PD), achieved on therapy. RESULTS: Median survival with anastrozole 1 mg was similar between patients who obtained CR/PR and SD (> or = 24 weeks). Similarly, no difference in survival was observed in patients treated with megestrol acetate who achieved CR/PR and SD. With both treatments patients with CR/PR and SD had improved survival over those patients with PD within 24 weeks. There was no difference between treatment arms for patients showing PD within 24 weeks. CONCLUSIONS: These data confirm that durable SD (> or = 24 weeks) is a clinically useful remission criterion in postmenopausal women with advanced breast cancer with predictive value for overall survival. It also confirms the value of this endpoint with anastrozole, a new generation aromatase inhibitor.
32 schema:genre research_article
33 schema:inLanguage en
34 schema:isAccessibleForFree false
35 schema:isPartOf N94ced91dbc3d4feabae4fc65a96e06af
36 N9961d27e318f4b63a0c5fd6e63d20fbd
37 sg:journal.1092777
38 schema:name Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer
39 schema:pagination 157-162
40 schema:productId N501bfced93ec4191b42eb42da91e7eb8
41 N65e1b600d1a1444c92d316fcea094db0
42 N8c92c136f6c44e8ba6f2cf7b76819d4e
43 Na883410af82f463984533216a5a6a355
44 Nc13ecf1f64704551a4bb6630fe4741bc
45 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037141890
46 https://doi.org/10.1023/a:1006391902868
47 schema:sdDatePublished 2019-04-10T14:06
48 schema:sdLicense https://scigraph.springernature.com/explorer/license/
49 schema:sdPublisher N4dab96fa73a44b4f8bc4cd702a865d08
50 schema:url http://link.springer.com/10.1023/A:1006391902868
51 sgo:license sg:explorer/license/
52 sgo:sdDataset articles
53 rdf:type schema:ScholarlyArticle
54 N05ee7b0cae384a99b33a0824f1809843 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
55 schema:name Europe
56 rdf:type schema:DefinedTerm
57 N1759b8cc43cb4770a66f6dae74d7039c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
58 schema:name Antineoplastic Agents, Hormonal
59 rdf:type schema:DefinedTerm
60 N26b84905ef1b41d6a13b94ffccef3ba7 rdf:first sg:person.015030714417.90
61 rdf:rest N6991d39cb1034b9b8594c618d076b3a6
62 N2cc5db6280b348918b0adeba7db2bb33 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
63 schema:name Dose-Response Relationship, Drug
64 rdf:type schema:DefinedTerm
65 N4dab96fa73a44b4f8bc4cd702a865d08 schema:name Springer Nature - SN SciGraph project
66 rdf:type schema:Organization
67 N501bfced93ec4191b42eb42da91e7eb8 schema:name dimensions_id
68 schema:value pub.1037141890
69 rdf:type schema:PropertyValue
70 N578e4803c7be4f3cac28937d65851777 rdf:first sg:person.0644622466.12
71 rdf:rest rdf:nil
72 N597b39e163894b06ad13599370862beb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Nitriles
74 rdf:type schema:DefinedTerm
75 N63be74ff62844af4bc250f25a77890cf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Survival Analysis
77 rdf:type schema:DefinedTerm
78 N64b0c3b4cb164f9d8a58473267c5bf49 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Enzyme Inhibitors
80 rdf:type schema:DefinedTerm
81 N65e1b600d1a1444c92d316fcea094db0 schema:name pubmed_id
82 schema:value 10674881
83 rdf:type schema:PropertyValue
84 N6991d39cb1034b9b8594c618d076b3a6 rdf:first sg:person.01264747205.84
85 rdf:rest N578e4803c7be4f3cac28937d65851777
86 N6b763fa9f6f34c9ba59501de656129a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Prospective Studies
88 rdf:type schema:DefinedTerm
89 N7ab0c64d0c054f3cabf23663bdc3632e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Double-Blind Method
91 rdf:type schema:DefinedTerm
92 N842546ac067d4373ba12022e50e0bf45 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Aromatase Inhibitors
94 rdf:type schema:DefinedTerm
95 N8c92c136f6c44e8ba6f2cf7b76819d4e schema:name readcube_id
96 schema:value b0ee88b7d380edf686d98efe9ae85fd2efaa46de1ec710caa12aab0c2ba6ae42
97 rdf:type schema:PropertyValue
98 N94ced91dbc3d4feabae4fc65a96e06af schema:issueNumber 2
99 rdf:type schema:PublicationIssue
100 N9961d27e318f4b63a0c5fd6e63d20fbd schema:volumeNumber 58
101 rdf:type schema:PublicationVolume
102 Na42453c62b12468986ac837091dfe892 rdf:first sg:person.07764637207.20
103 rdf:rest Nbc008ec017c74828980634d7894e3684
104 Na883410af82f463984533216a5a6a355 schema:name doi
105 schema:value 10.1023/a:1006391902868
106 rdf:type schema:PropertyValue
107 Nb039f62a09c648e3aef307c1ae2234c6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Megestrol Acetate
109 rdf:type schema:DefinedTerm
110 Nb9f0f6ca1a0148f5b1fb2fa3b0c84be4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Humans
112 rdf:type schema:DefinedTerm
113 Nbc008ec017c74828980634d7894e3684 rdf:first sg:person.01005610111.35
114 rdf:rest N26b84905ef1b41d6a13b94ffccef3ba7
115 Nbcec6cca4fd94ee2bc6372d68169972a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Breast Neoplasms
117 rdf:type schema:DefinedTerm
118 Nc11e2f2028a543da80ebba3c3884b1ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Postmenopause
120 rdf:type schema:DefinedTerm
121 Nc13ecf1f64704551a4bb6630fe4741bc schema:name nlm_unique_id
122 schema:value 8111104
123 rdf:type schema:PropertyValue
124 Ncbf50214f8e0489db42af7b0e70e2f9f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Female
126 rdf:type schema:DefinedTerm
127 Nd0e6d00e56a04dde8ab70cc824c5e054 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name United States
129 rdf:type schema:DefinedTerm
130 Nd14243beb21543a4a79ca31a0bc4767a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Triazoles
132 rdf:type schema:DefinedTerm
133 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
134 schema:name Medical and Health Sciences
135 rdf:type schema:DefinedTerm
136 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
137 schema:name Oncology and Carcinogenesis
138 rdf:type schema:DefinedTerm
139 sg:journal.1092777 schema:issn 0167-6806
140 1573-7217
141 schema:name Breast Cancer Research and Treatment
142 rdf:type schema:Periodical
143 sg:person.01005610111.35 schema:affiliation https://www.grid.ac/institutes/grid.415720.5
144 schema:familyName Howell
145 schema:givenName A.
146 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01005610111.35
147 rdf:type schema:Person
148 sg:person.01264747205.84 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
149 schema:familyName von Euler
150 schema:givenName M.
151 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264747205.84
152 rdf:type schema:Person
153 sg:person.015030714417.90 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
154 schema:familyName Buzdar
155 schema:givenName A.
156 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015030714417.90
157 rdf:type schema:Person
158 sg:person.0644622466.12 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
159 schema:familyName Lee
160 schema:givenName D.
161 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644622466.12
162 rdf:type schema:Person
163 sg:person.07764637207.20 schema:affiliation https://www.grid.ac/institutes/grid.412920.c
164 schema:familyName Robertson
165 schema:givenName J.F.R.
166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07764637207.20
167 rdf:type schema:Person
168 https://doi.org/10.1002/(sici)1097-0142(19980915)83:6<1142::aid-cncr13>3.0.co;2-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005407624
169 rdf:type schema:CreativeWork
170 https://doi.org/10.1016/0014-2964(77)90234-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014483121
171 rdf:type schema:CreativeWork
172 https://doi.org/10.1016/0277-5379(88)90046-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045342488
173 rdf:type schema:CreativeWork
174 https://doi.org/10.1016/0277-5379(89)90259-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007284388
175 rdf:type schema:CreativeWork
176 https://doi.org/10.1016/s0959-8049(97)00178-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030310702
177 rdf:type schema:CreativeWork
178 https://doi.org/10.1023/a:1008226721932 schema:sameAs https://app.dimensions.ai/details/publication/pub.1056302667
179 rdf:type schema:CreativeWork
180 https://doi.org/10.1200/jco.1996.14.7.2000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082907367
181 rdf:type schema:CreativeWork
182 https://doi.org/10.1200/jco.1998.16.2.453 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083213024
183 rdf:type schema:CreativeWork
184 https://doi.org/10.1200/jco.1999.17.1.52 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074511209
185 rdf:type schema:CreativeWork
186 https://www.grid.ac/institutes/grid.240145.6 schema:alternateName The University of Texas MD Anderson Cancer Center
187 schema:name D Anderson Cancer Center, Houston, Texas, USA
188 rdf:type schema:Organization
189 https://www.grid.ac/institutes/grid.412920.c schema:alternateName Nottingham City Hospital
190 schema:name Department of Surgery, City Hospital, Nottingham, UK
191 rdf:type schema:Organization
192 https://www.grid.ac/institutes/grid.415720.5 schema:alternateName The Christie Hospital
193 schema:name Christie Hospital, Manchester, UK
194 rdf:type schema:Organization
195 https://www.grid.ac/institutes/grid.417815.e schema:alternateName AstraZeneca (United Kingdom)
196 schema:name AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, UK
197 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...